LLYEli Lilly and Company
# 11 · $1,273.46 (-2.54%) · $1.14T · Healthcare
Rango 52 semanas
Datos de mercado
- P/E
- 42.75
- 1M
- +7.75%
- 1A
- +56.08%
- Rentab.
- 0.53%
- RSI
- 69.96
- MACD
- +0.87%
Desglose
Por qué
- PEG of 0.45
- earnings growth of 94.9%
- revenue growth of 44.7%
- ROE of 78.8%
- profit margin of 33.5%
- margin and ROA expanding YoY
- 12-1 momentum return of 44.9%
- trading 17.6% above 200d SMA
- MACD histogram positive
- EPS vs. estimates: +20.4% on average
El razonamiento lo genera el motor de scoring (en inglés).
Piotroski F-Score
8
8 / 9 checks superados
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Señales de riesgo
- Altman Z in grey zoneMedia
Z-Score 2.16 (1.81–2.99) — not clearly safe
- Earnings quality (accruals)Media
operating cash flow below reported net income — profits not backed by cash
- Product revenue concentrationInfo
94% of revenue from Products
Análisis de la empresa
Business Overview Eli Lilly and Company (LLY) is a research-based biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines across major therapeutic areas including diabetes/obesity (incretins), oncology, immunology/dermatology, and neuroscience; revenue is primarily generated from branded drug sales to wholesalers, pharmacies, hospitals, and health systems. Market Position Lilly is a leading global pharma company with strong competitive positioning in incretin-based cardiometabolic therapies (e.g., Mounjaro, Zepbound) and a scaled innovation engine spanning clinical development and manufacturing, supported by a large commercial footprint and expanding capacity to meet demand. Key Segments Lilly operates as a single pharmaceutical segment, with major franchises typically organized around Cardiometabolic Health, Oncology, Immunology, and Neuroscience.
Resumen generado por IA a partir de datos de terceros; puede contener errores. No constituye asesoramiento financiero ni recomendación de inversión.
Periodo: 2021-12-31 → 2025-12-31